bimekizumab
ucb pharmaceuticals
['bimekizumab']
congress #acr22 | summarised the be active paper on bimekizumab for #psoriaticarthritis in the a&amp;r &amp; ard editors picks 2022 session. most common teaes were nasopharyngitis, upper rti &amp; candida. at 152 wks (nri): acr50=52.9%, mda=51.5% &amp; pasi100=57.7% 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.